603456 九洲药业
已收盘 01-12 15:00:00
资讯
新帖
简况
每周股票复盘：九洲药业（603456）瑞博制药获高新认定享税收优惠
证券之星 · 01-11 02:40
每周股票复盘：九洲药业（603456）瑞博制药获高新认定享税收优惠
每周股票复盘：九洲药业（603456）子公司投1000万参设医药基金
证券之星 · 2025-12-28
每周股票复盘：九洲药业（603456）子公司投1000万参设医药基金
九洲药业(603456.SH)子公司拟参与投资嘉兴隆峰创业投资合伙企业(有限合伙)
智通财经网 · 2025-12-22
九洲药业(603456.SH)子公司拟参与投资嘉兴隆峰创业投资合伙企业(有限合伙)
九洲药业（603456）披露部分募投项目延期公告，12月9日股价下跌0.71%
证券之星 · 2025-12-09
九洲药业（603456）披露部分募投项目延期公告，12月9日股价下跌0.71%
九洲药业(603456.SH)：西格列汀二甲双胍缓释片ANDA通过美国FDA上市许可批准
智通财经 · 2025-11-27
九洲药业(603456.SH)：西格列汀二甲双胍缓释片ANDA通过美国FDA上市许可批准
九洲药业（603456）披露收到化学原料药上市申请批准通知书，11月24日股价上涨1.56%
证券之星 · 2025-11-24
九洲药业（603456）披露收到化学原料药上市申请批准通知书，11月24日股价上涨1.56%
九洲药业(603456.SH)：甲苯磺酸艾多沙班化学原料药上市申请获批准
智通财经 · 2025-11-24
九洲药业(603456.SH)：甲苯磺酸艾多沙班化学原料药上市申请获批准
11月21日九洲药业跌5.48%，信澳健康中国混合A基金重仓该股
证券之星 · 2025-11-21
11月21日九洲药业跌5.48%，信澳健康中国混合A基金重仓该股
每周股票复盘：九洲药业（603456）实控人变更为花莉蓉、花晓慧
证券之星 · 2025-11-16
每周股票复盘：九洲药业（603456）实控人变更为花莉蓉、花晓慧
11月14日九洲药业涨5.51%，信澳健康中国混合A基金重仓该股
证券之星 · 2025-11-14
11月14日九洲药业涨5.51%，信澳健康中国混合A基金重仓该股
九洲药业(603456.SH)子公司获得甲苯磺酸艾多沙班药品注册证书
智通财经网 · 2025-11-14
九洲药业(603456.SH)子公司获得甲苯磺酸艾多沙班药品注册证书
九洲药业最新公告：非独立董事辞职暨选举职工代表董事
证券之星 · 2025-11-12
九洲药业最新公告：非独立董事辞职暨选举职工代表董事
九洲药业最新公告：选举花莉蓉为执行董事并任法定代表人
证券之星 · 2025-11-12
九洲药业最新公告：选举花莉蓉为执行董事并任法定代表人
九洲药业（603456）披露控股股东及一致行动人上层股权结构内部调整暨实际控制人减少提示性公告，11月11日股价上涨0.05%
证券之星 · 2025-11-11
九洲药业（603456）披露控股股东及一致行动人上层股权结构内部调整暨实际控制人减少提示性公告，11月11日股价上涨0.05%
每周股票复盘：九洲药业（603456）临时股东大会审议通过取消监事会
证券之星 · 2025-11-02
每周股票复盘：九洲药业（603456）临时股东大会审议通过取消监事会
每周股票复盘：九洲药业（603456）拟取消监事会并修订章程
证券之星 · 2025-10-26
每周股票复盘：九洲药业（603456）拟取消监事会并修订章程
九洲药业（603456）披露拟取消监事会并修订公司章程议案，10月21日股价上涨2.6%
证券之星 · 2025-10-21
九洲药业（603456）披露拟取消监事会并修订公司章程议案，10月21日股价上涨2.6%
九洲药业（603456）2025年三季报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 2025-10-17
九洲药业（603456）2025年三季报简析：营收净利润同比双双增长，盈利能力上升
九洲药业(603456.SH)发布前三季度业绩，归母净利润7.48亿元，同比增长18.51%
智通财经 · 2025-10-15
九洲药业(603456.SH)发布前三季度业绩，归母净利润7.48亿元，同比增长18.51%
每周股票复盘：九洲药业（603456）将召开2025年Q3业绩说明会
证券之星 · 2025-10-12
每周股票复盘：九洲药业（603456）将召开2025年Q3业绩说明会
加载更多
公司概况
公司名称：
浙江九洲药业股份有限公司
所属行业：
医药制造业
上市日期：
2014-10-10
主营业务：
浙江九洲药业股份有限公司的主营业务是为全球制药公司、生物科技公司、科研机构等提供一站式的医药定制研发和生产（CDMO）服务。公司的主要产品是小分子化学药物、多肽药物、偶联药物和小核酸药物。公司荣获2025中国医药CDMO企业20强、2024年度中国医药工业主营业务收入前100位企业、2024年EcoVadis企业社会责任评级“金牌”认证、全球优选合作伙伴奖、ESG责任企业奖等多项荣誉。
发行价格：
15.43
{"stockData":{"symbol":"603456","market":"SH","secType":"STK","nameCN":"九洲药业","latestPrice":19.44,"timestamp":1768201200000,"preClose":19.44,"halted":0,"volume":22973051,"delay":0,"changeRate":0,"floatShares":889000000,"shares":889000000,"eps":0.8128,"marketStatus":"已收盘","change":0,"latestTime":"01-12 15:00:00","open":19.55,"high":19.7,"low":19.19,"amount":445000000,"amplitude":0.0262,"askPrice":19.45,"askSize":277,"bidPrice":19.44,"bidSize":783,"shortable":0,"etf":0,"ttmEps":0.8128,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768267800000},"marketStatusCode":5,"adr":0,"adjPreClose":19.44,"symbolType":"stock","openAndCloseTimeList":[[1768181400000,1768188600000],[1768194000000,1768201200000]],"highLimit":21.38,"lowLimit":17.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":889446028,"isCdr":false,"pbRate":1.97,"roa":"--","peRate":23.917323,"roe":"8.57%","epsLYR":0.68,"committee":-0.04208,"marketValue":17291000000,"turnoverRate":0.0258,"status":2,"floatMarketCap":17291000000},"requestUrl":"/m/hq/s/603456","defaultTab":"news","newsList":[{"id":"2602535663","title":"每周股票复盘：九洲药业（603456）瑞博制药获高新认定享税收优惠","url":"https://stock-news.laohu8.com/highlight/detail?id=2602535663","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602535663?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:40","pubTimestamp":1768070422,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，九洲药业报收于19.44元，较上周的17.9元上涨8.6%。本周，九洲药业1月9日盘中最高价报19.48元。本周关注点公司公告汇总：全资子公司瑞博制药获高新技术企业认定，2025-2027年按15%税率缴所得税公司公告汇总浙江九洲药业股份有限公司全资子公司浙江瑞博制药有限公司通过高新技术企业认定，证书编号GR202533010708，发证日期2025年12月19日，有效期三年。2025年至2027年期间，瑞博制药将享受15%的企业所得税优惠税率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK1574","BK0070","BK1191","BK0239","01477"],"gpt_icon":0},{"id":"2594624141","title":"每周股票复盘：九洲药业（603456）子公司投1000万参设医药基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2594624141","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594624141?lang=zh_cn&edition=full","pubTime":"2025-12-28 01:50","pubTimestamp":1766857815,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，九洲药业报收于18.14元，较上周的18.29元下跌0.82%。本周，九洲药业12月25日盘中最高价报18.45元。本周关注点公司公告汇总：九洲药业子公司认缴1000万元参与投资嘉兴隆峰创投，布局医药领域。公司公告汇总浙江九洲药业股份有限公司全资子公司浙江宏洲股权投资有限公司参与投资嘉兴隆峰创业投资合伙企业，认缴出资1,000万元，占总认缴出资额的12.987%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0070","BK0239","160635"],"gpt_icon":0},{"id":"2593251100","title":"九洲药业(603456.SH)子公司拟参与投资嘉兴隆峰创业投资合伙企业(有限合伙)","url":"https://stock-news.laohu8.com/highlight/detail?id=2593251100","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593251100?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:37","pubTimestamp":1766392677,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业 发布公告，公司全资子公司宏洲投资拟参与投资嘉兴隆峰创业投资合伙企业。合伙企业认缴出资总额为7700万元，宏洲投资将作为有限合伙人以自有资金认缴出资额为1000万元，占合伙企业认缴出资总额的12.987%。合伙企业投资方向：主要投资于新药研发、医疗器械研发项目等医药相关领域，主要包括优质的新兴医疗企业，包括但不限于新药、创新药、医疗器械、医疗服务、诊断、生物技术、医药外包研发企业等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["603456","BK0239","BK0070"],"gpt_icon":0},{"id":"2590344254","title":"九洲药业（603456）披露部分募投项目延期公告，12月9日股价下跌0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590344254","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590344254?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:11","pubTimestamp":1765289486,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘，九洲药业报收于18.3元，较前一交易日下跌0.71%，最新总市值为162.77亿元。该股当日开盘18.39元，最高18.75元，最低18.25元，成交额达2.24亿元，换手率为1.36%。截至2025年6月30日，该项目募集资金承诺投资总额28,000.00万元，实际投入23,118.49万元，投入进度82.57%。公告称，延期主要因工程结算进度等不可控因素，项目延期不涉及实施主体、方式、投资总额及内容变更，未改变募集资金用途。保荐机构华泰联合证券对该事项无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900040284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0070","BK0239"],"gpt_icon":0},{"id":"2586669210","title":"九洲药业(603456.SH)：西格列汀二甲双胍缓释片ANDA通过美国FDA上市许可批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2586669210","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586669210?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:04","pubTimestamp":1764230687,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业 发布公告，近日，公司控股子公司浙江九洲生物医药有限公司向美国食品药品监督管理局提交的西格列汀二甲双胍缓释片简略新药申请的已获得美国FDA的暂时批准。西格列汀二甲双胍缓释片主要用于经二甲双胍单药治疗血糖仍控制不佳或正在接受二者联合治疗的2型糖尿病患者。西格列汀二甲双胍缓释片的原研药为JanumetXR，由默沙东公司研发，于2012年2月在美国上市。根据公开数据显示，2024年该药品美国市场销售额约11亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"九洲药业(603456.SH)：西格列汀二甲双胍缓释片ANDA通过美国FDA上市许可批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK0239","603456"],"gpt_icon":0},{"id":"2585604674","title":"九洲药业（603456）披露收到化学原料药上市申请批准通知书，11月24日股价上涨1.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585604674","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585604674?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:13","pubTimestamp":1763993603,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，九洲药业报收于18.91元，较前一交易日上涨1.56%，最新总市值为168.19亿元。该股当日开盘18.75元，最高19.06元，最低18.61元，成交额达3.34亿元，换手率为1.99%。公司近日发布公告称，浙江九洲药业股份有限公司近日收到国家药品监督管理局颁发的关于甲苯磺酸艾多沙班的《化学原料药上市申请批准通知书》，批准该原料药上市申请。该原料药主要用于预防非瓣膜性房颤患者的卒中及全身性栓塞，以及治疗或预防深静脉血栓和肺栓塞。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","603456"],"gpt_icon":0},{"id":"2585549294","title":"九洲药业(603456.SH)：甲苯磺酸艾多沙班化学原料药上市申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2585549294","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585549294?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:15","pubTimestamp":1763972158,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业(603456.SH)公告，公司收到国家药品监督管理局颁发的关于甲苯磺酸艾多沙班的《化学原料药上市申请批准通知书》。甲苯磺酸艾多沙班是一种口服抗凝药物，主要用于预防非瓣膜性房颤患者的卒中及全身性栓塞，以及治疗或预防深静脉血栓和肺栓塞。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"九洲药业(603456.SH)：甲苯磺酸艾多沙班化学原料药上市申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603456","BK0070","BK0239"],"gpt_icon":0},{"id":"2585197219","title":"11月21日九洲药业跌5.48%，信澳健康中国混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585197219","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585197219?lang=zh_cn&edition=full","pubTime":"2025-11-21 15:41","pubTimestamp":1763710865,"startTime":"0","endTime":"0","summary":"证券之星消息，11月21日九洲药业跌5.48%，收盘报18.62元，换手率3.88%，成交量34.5万手，成交额6.54亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为信达澳亚基金的信澳健康中国混合A。信澳健康中国混合A目前规模为5.1亿元，最新净值2.244，较上一交易日下跌0.18%，近一年上涨12.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100018583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0239","BK0070"],"gpt_icon":0},{"id":"2583659021","title":"每周股票复盘：九洲药业（603456）实控人变更为花莉蓉、花晓慧","url":"https://stock-news.laohu8.com/highlight/detail?id=2583659021","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583659021?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:03","pubTimestamp":1763233391,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，九洲药业报收于21.46元，较上周的19.43元上涨10.45%。转让完成后，花轩德不再直接或间接持有公司任何股权，不再为实际控制人，公司实际控制人变更为花莉蓉、花晓慧二人，符合相关法律法规规定。九洲药业发布提示性公告，控股股东中贝集团及一致行动人台州歌德上层股权结构发生内部调整，实际控制人由花轩德、花莉蓉、花晓慧变更为花莉蓉、花晓慧。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","603456"],"gpt_icon":0},{"id":"2583573729","title":"11月14日九洲药业涨5.51%，信澳健康中国混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583573729","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583573729?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:29","pubTimestamp":1763108972,"startTime":"0","endTime":"0","summary":"证券之星消息，11月14日九洲药业涨5.51%创60日新高，收盘报21.46元，换手率7.26%，成交量64.6万手，成交额13.73亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为信达澳亚基金的信澳健康中国混合A。信澳健康中国混合A目前规模为5.1亿元，最新净值2.349，较上一交易日上涨1.08%，近一年上涨14.53%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400025700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0239","BK0070"],"gpt_icon":0},{"id":"2583520606","title":"九洲药业(603456.SH)子公司获得甲苯磺酸艾多沙班药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2583520606","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583520606?lang=zh_cn&edition=full","pubTime":"2025-11-14 15:36","pubTimestamp":1763105770,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业 发布公告，近日，公司全资子公司九洲生物医药(台州)有限公司收到国家药品监督管理局核准签发的甲苯磺酸艾多沙班片的《药品注册证书》。甲苯磺酸艾多沙班是一种口服抗凝药物，主要用于预防非瓣膜性房颤患者的卒中及全身性栓塞，以及治疗或预防深静脉血栓和肺栓塞。目前国内获得该药品注册证书的生产厂家为海南先声药业有限公司、山东新时代药业有限公司等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"九洲药业(603456.SH)子公司获得甲苯磺酸艾多沙班药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["603456","BK0070","BK0239"],"gpt_icon":0},{"id":"2582247963","title":"九洲药业最新公告：非独立董事辞职暨选举职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2582247963","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582247963?lang=zh_cn&edition=full","pubTime":"2025-11-12 18:00","pubTimestamp":1762941627,"startTime":"0","endTime":"0","summary":"九洲药业公告称，公司董事会收到非独立董事LIYUANQIANG的辞职报告，因公司治理结构调整，LIYUANQIANG申请辞去非独立董事职务。根据相关规定，其辞职报告自送达董事会之日起生效。LIYUANQIANG将继续担任公司执行副总裁职务。此外，公司于2025年11月12日召开职工代表大会，选举陈丽月为公司第八届董事会职工代表董事，任期自选举通过之日起至第八届董事会任期届满之日止。陈丽月符合相关法律法规、规范性文件及《公司章程》有关董事任职的资格和条件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200029735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0239","BK0070"],"gpt_icon":0},{"id":"2582249503","title":"九洲药业最新公告：选举花莉蓉为执行董事并任法定代表人","url":"https://stock-news.laohu8.com/highlight/detail?id=2582249503","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582249503?lang=zh_cn&edition=full","pubTime":"2025-11-12 17:51","pubTimestamp":1762941066,"startTime":"0","endTime":"0","summary":"九洲药业(603456.SH)公告称，公司第八届董事会第十八次会议于2025年11月12日召开，会议选举花莉蓉为代表公司执行公司事务的董事，并担任公司法定代表人，任期至公司第八届董事会任期届满之日止。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200029392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","603456","BK0239"],"gpt_icon":0},{"id":"2582362780","title":"九洲药业（603456）披露控股股东及一致行动人上层股权结构内部调整暨实际控制人减少提示性公告，11月11日股价上涨0.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582362780","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582362780?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:16","pubTimestamp":1762870585,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，九洲药业报收于19.88元，较前一交易日上涨0.05%，最新总市值为176.82亿元。该股当日开盘19.88元，最高19.99元，最低19.6元，成交额达4.41亿元，换手率为2.5%。公告显示，公司控股股东中贝集团及其一致行动人台州歌德的上层股权结构发生内部调整，实际控制人由花轩德、花莉蓉、花晓慧变更为花莉蓉、花晓慧。本次调整为家族成员之间的股权调整，公司控股股东不变，直接持股和间接持股数量均未变化，不影响公司经营独立性和生产经营。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100040751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603456","BK0070"],"gpt_icon":0},{"id":"2580737884","title":"每周股票复盘：九洲药业（603456）临时股东大会审议通过取消监事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2580737884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580737884?lang=zh_cn&edition=full","pubTime":"2025-11-02 02:32","pubTimestamp":1762021931,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：九洲药业2025年第一次临时股东大会审议通过《关于取消监事会并修订〈公司章程〉的议案》，同意票占99.83%。公司公告汇总浙江九洲药业股份有限公司2025年第一次临时股东大会于2025年10月31日召开，会议由董事会召集，采取现场与网络投票相结合方式。浙江九洲药业股份有限公司2025年第一次临时股东大会决议公告显示，出席会议的股东及代理人共524人，代表有表决权股份总数的48.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","603456"],"gpt_icon":0},{"id":"2578504940","title":"每周股票复盘：九洲药业（603456）拟取消监事会并修订章程","url":"https://stock-news.laohu8.com/highlight/detail?id=2578504940","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578504940?lang=zh_cn&edition=full","pubTime":"2025-10-26 02:33","pubTimestamp":1761417191,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，九洲药业报收于19.28元，较上周的18.85元上涨2.28%。本周，九洲药业10月24日盘中最高价报19.75元。本周关注点公司公告汇总：九洲药业拟取消监事会，由董事会审计委员会承接其职能。公司公告汇总浙江九洲药业股份有限公司将于2025年10月31日召开2025年第一次临时股东大会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603456","BK0070"],"gpt_icon":0},{"id":"2577187919","title":"九洲药业（603456）披露拟取消监事会并修订公司章程议案，10月21日股价上涨2.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577187919","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577187919?lang=zh_cn&edition=full","pubTime":"2025-10-21 22:13","pubTimestamp":1761055996,"startTime":"0","endTime":"0","summary":"截至2025年10月21日收盘，九洲药业报收于19.33元，较前一交易日上涨2.6%，最新总市值为171.93亿元。该股当日开盘18.9元，最高19.33元，最低18.73元，成交额达4.65亿元，换手率为2.74%。近日，浙江九洲药业股份有限公司发布2025年第一次临时股东大会会议资料，宣布将于2025年10月31日召开临时股东大会，审议多项重要议案。其中最受投资者关注的是关于取消监事会并修订《公司章程》的议案。该议案属于特别决议议案，需经出席会议股东所持表决权三分之二以上通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100036907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0070","BK0239"],"gpt_icon":0},{"id":"2576779475","title":"九洲药业（603456）2025年三季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2576779475","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576779475?lang=zh_cn&edition=full","pubTime":"2025-10-17 06:01","pubTimestamp":1760652116,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期九洲药业发布2025年三季报。截至本报告期末，公司营业总收入41.6亿元，同比上升4.92%，归母净利润7.48亿元，同比上升18.51%。按单季度数据看，第三季度营业总收入12.9亿元，同比上升7.37%，第三季度归母净利润2.22亿元，同比上升42.3%。本报告期九洲药业盈利能力上升，毛利率同比增幅8.06%，净利率同比增幅12.75%。持有九洲药业最多的基金为京管泰富科技驱动混合A，目前规模为0.57亿元，最新净值1.4123，较上一交易日下跌1.4%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700004573.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456"],"gpt_icon":0},{"id":"2575201668","title":"九洲药业(603456.SH)发布前三季度业绩，归母净利润7.48亿元，同比增长18.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575201668","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575201668?lang=zh_cn&edition=full","pubTime":"2025-10-15 16:32","pubTimestamp":1760517141,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业(603456.SH)发布2025年三季度报告，前三季度，公司实现营业收入41.6亿元，同比增长4.92%。归属于上市公司股东的净利润7.48亿元，同比增长18.51%。归属于上市公司股东的扣除非经常性损益的净利润7.46亿元，同比增长20.67%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1355302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603456"],"gpt_icon":0},{"id":"2574245768","title":"每周股票复盘：九洲药业（603456）将召开2025年Q3业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2574245768","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574245768?lang=zh_cn&edition=full","pubTime":"2025-10-12 01:43","pubTimestamp":1760204590,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，九洲药业报收于19.85元，较上周的19.45元上涨2.06%。本周，九洲药业10月9日盘中最高价报20.75元。本周关注点公司公告汇总：九洲药业将于2025年10月16日召开第三季度业绩说明会，投资者可提前提交问题。公司公告汇总浙江九洲药业股份有限公司将于2025年10月16日（星期四）11:00-12:00召开2025年第三季度业绩说明会，会议通过上海证券交易所上证路演中心网络互动方式进行，网址为http://roadshow.sseinfo.com/。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","603456"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768262588972,"stockEarnings":[{"period":"1week","weight":0.0457},{"period":"1month","weight":0.0658},{"period":"3month","weight":-0.0056},{"period":"6month","weight":0.2037},{"period":"1year","weight":0.5838},{"period":"ytd","weight":0.086}],"compareEarnings":[{"period":"1week","weight":0.0353},{"period":"1month","weight":0.0709},{"period":"3month","weight":0.0776},{"period":"6month","weight":0.1888},{"period":"1year","weight":0.3146},{"period":"ytd","weight":0.0495}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江九洲药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"59157人(较上一季度增加10.22%)","perCapita":"15035股","listingDate":"2014-10-10","address":"浙江省台州市椒江区外沙路99号","registeredCapital":"88944万元","survey":" 浙江九洲药业股份有限公司的主营业务是为全球制药公司、生物科技公司、科研机构等提供一站式的医药定制研发和生产（CDMO）服务。公司的主要产品是小分子化学药物、多肽药物、偶联药物和小核酸药物。公司荣获2025中国医药CDMO企业20强、2024年度中国医药工业主营业务收入前100位企业、2024年EcoVadis企业社会责任评级“金牌”认证、全球优选合作伙伴奖、ESG责任企业奖等多项荣誉。","listedPrice":15.43},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九洲药业(603456)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九洲药业(603456)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九洲药业,603456,九洲药业股票,九洲药业股票老虎,九洲药业股票老虎国际,九洲药业行情,九洲药业股票行情,九洲药业股价,九洲药业股市,九洲药业股票价格,九洲药业股票交易,九洲药业股票购买,九洲药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九洲药业(603456)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九洲药业(603456)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}